<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863003</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0515</org_study_id>
    <nct_id>NCT02863003</nct_id>
  </id_info>
  <brief_title>Multicenter Database of Patients With Germ Cell Tumor</brief_title>
  <official_title>Multicenter Database of Patients With Germ Cell Tumor in Order to Characterize Clinicopathologically and to Evaluate Cancer Treatment Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      Retrospective and prospective cohort of patients with germ cell tumor in treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to create a multicenter database in order to&#xD;
      characterize epidemiologically and clinicopathologically patients with germ cell tumor and&#xD;
      evaluate the prognosis and clinical outcomes during cancer treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>16 Years</target_duration>
  <primary_outcome>
    <measure>Brazilian multicenter database in order to collect and analyze data from diagnosis and treatment of patients with germ cell tumor</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of demographic characteristics of testicular germ cell tumor patients in Brazil</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical and pathological characteristics of testicular germ cell tumor patients in Brazil.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment according to staging and relapse of patients diagnosed with testicular germ cell tumor in Brazil</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of patients diagnosed with germ cell tumor stage 1.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients diagnosed with germ cell tumor stage 1.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of patients diagnosed with germ cell tumor stages 2 and 3.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients diagnosed with germ cell tumor stages 2 and 3.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International prognostic factors in patients with advanced germ cell tumor (stages 2 and 3) stablished by the International Germ Cell Cancer Collaborative Group in brazilian patients.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment outcome in different populations: in patients with brain metastasis, patients with germinative tumor extragonodal, surgery outcome in patients with nonseminomous tumor and ressection of residual lesion after chemotherapy</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival of patients diagnosed with disease relapse after first line chemotherapy</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients diagnosed with disease relapse after first line chemotherapy</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic model after first line treatment failure with cisplatin, stablished by the International Prognostic Factors Study Group in brazilian patients.</measure>
    <time_frame>From 2000 to 2025</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1315</enrollment>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Men with diagnosis of testicular, retroperitonium or mediastinal primary tumor.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients with diagnosis of testicular, retroperitoneum or mediastinal primary&#xD;
             tumor.&#xD;
&#xD;
          -  Histological confirmation of germ cell tumor or clinical condition based on the&#xD;
             elevation of tumor markers (AFP, HCG e/ou DHL) associated to testicular mass or/and&#xD;
             retroperitoneal lymphnode enlargement or/and mediastinal mass.&#xD;
&#xD;
          -  Medical records of the disease and treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients diagnosed with ovary germ cell tumor&#xD;
&#xD;
          -  Male patients diagnosed with germ cell tumor in other locations.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diogo Bastos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPO - Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São José</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

